Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01406639 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study withdrawn due to lack of study population.

Conditions

Hereditary Hemorrhagic Telangiectasia (HHT)
Nosebleeds

Interventions

DRUG: Ranibizumab

Sponsor

University of California, San Diego

Collaborators

[object Object]